Trials / Withdrawn
WithdrawnNCT00670384
Phase 2 Study in Adults Sensitized to Short Ragweed
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study of Sublingual Immunotherapy in Adults Sensitized to the Standardized Allergenic Extract, Short Ragweed (Ambrosia Artemisiifolia)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Antigen Laboratories, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to identify an effective dose of allergen-specific immunotherapy for short ragweed (Ambrosia artemisiifolia) administered by an oral/sublingual route.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Standardized Allergenic Extract, Short Ragweed (Ambrosia artemisiifolia) | Sublingual drops |
| BIOLOGICAL | Placebo | Sublingual drops |
Timeline
- First posted
- 2008-05-01
- Last updated
- 2014-01-09
Source: ClinicalTrials.gov record NCT00670384. Inclusion in this directory is not an endorsement.